3 Best Stocks to Buy Now, 9/25/2025, According to Top Analysts

Wall Street's sharpest minds reveal where to park your cash before Q4 kicks in.

Analysts Triple Down on These Picks

Forget the noise—these three names keep appearing on every top performer's radar. Massive institutional buying signals confidence while retail investors chase meme stocks.

Fundamentals Actually Matter Again

With volatility spiking, old-school metrics like P/E ratios and cash flow suddenly look sexy. These picks combine strong balance sheets with sector-leading growth potential.

Timing the Market vs Time in Market

September's dip creates entry points that won't last. Analysts project double-digit upside through year-end—if you can stomach the occasional red day.

Because sometimes the best trade is ignoring your broker's hourly newsletter and buying what actually makes money.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

(CTNM) – Contineum is a California-based biotech company that is developing innovative therapies to treat rare and complex diseases such as progressive multiple sclerosis (a long-term brain and spinal cord disease) and idiopathic pulmonary fibrosis (a lung disease that causes scarring inside the lungs). Today, Leerink Partners analyst Faisal Khurshid commenced this coverage of the stock with a price target of $20 per share. This is even as all five Top analysts that recently rated the stock gave it their Buy recommendation. Taken together, their 12-month price target suggests a 121% upside potential.

(COLD) – Americold is a Georgia-based real estate investment trust that owns and operates temperature-controlled warehouses. Today, Truist Financial analyst Ki Bin Kim maintained its price of between $20 and $17 for the stock. Furthermore, all four Top analysts covering this stock gave it a Buy rating. Overall, their 12-month price target indicates a possible 65.44% growth potential.

(JHX) – James Hardie is a multinational producer of weather-resistant building materials—like fiber cement and gypsum boards—used in homes and commercial buildings across the U.S., Australia, and beyond. Today, Truist Financial analyst Keith Hughes reaffirmed his Buy rating for the stock without suggesting a price target. However, all four Top analysts who recently reviewed this stock have given it a Buy rating. Across the board, their 12-month price target indicates a potential growth of 52.01% from its current level.

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.